# Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

> **NCT05258669** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Ocugen** · enrollment: 400 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** BBV152

## Key facts

- **NCT ID:** NCT05258669
- **Lead sponsor:** Ocugen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-20
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-10-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258669, "Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05258669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*